Design and evaluation of IKK-activated GSK3β inhibitory peptide as an inflammation-responsive anti-colitic therapeutic
- 16 August 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (19) , 6584-6596
Abstract
Colon-targeted cell-permeable IKK-activated GSK3β inhibitory peptide (CTP-IAGIP in a colon-targeted capsule) is an inflammation-responsive anti-colitic therapeutics.Keywords
Funding Information
- Ministry of Education (2018R1D1A3B07045694)
This publication has 43 references indexed in Scilit:
- Future directions for peptide therapeutics developmentDrug Discovery Today, 2013
- Glycogen synthase kinase 3: A point of convergence for the host inflammatory responseCytokine, 2011
- Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)Trends in Immunology, 2010
- Characterization and development of novel small-molecules inhibiting GSK3 and activating WntsignalingMolecular BioSystems, 2009
- Glycogen synthase kinase 3: more than a namesakeBritish Journal of Pharmacology, 2009
- Direct Inhibition of GSK3β by the Phosphorylated Cytoplasmic Domain of LRP6 in Wnt/β-Catenin SignalingPLOS ONE, 2008
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006
- Cytoplasmic transduction peptide (CTP): New approach for the delivery of biomolecules into cytoplasm in vitro and in vivoExperimental Cell Research, 2006
- Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase‐3βBritish Journal of Pharmacology, 2006
- Peptides Corresponding to the N and C Termini of IκB-α, -β, and -ε as Probes of the Two Catalytic Subunits of IκB Kinase, IKK-1 and IKK-2Journal of Biological Chemistry, 1999